A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 32
- Population
- ALL · 18 Years
- Duration
- 2015-12-21 to 2018-02-01
- Intervention
- Sirolimus
- Comparator
- Not reported
- Outcomes measured
- Number of Participants Who Met the Study-defined Composite Safety Endpoint — Screening to study week 32 (week 20 of Sir…; Efficacy - Immunologic: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma — At study…; Efficacy - Immunologic: Change in HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma — At study we…; Efficacy - Virologic: CD4+ T-cell-associated HIV-1 RNA — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Efficacy - Virologic: Change in CD4+ T-cell-associated HIV-1 RNA — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Efficacy - Virologic: Plasma HIV-1 RNA by SCA — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Efficacy - Virologic: Change in Plasma HIV-1 RNA by SCA — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Measurement of CD4+ T-cell Counts — At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44; Change in CD4+ T-cell Counts — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Measurement of HIV-1 RNA Levels — weeks 0, 12, (pre-Sirolimus) 16, 24, 32 (4, 12, 20 weeks on Sirolimus) and 44; Cell-associated HIV-1 DNA Levels in Total CD4+ Cells — At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus)…; Change in Cell-associated HIV-1 DNA Levels in Total CD4+ Cells — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Measurement of HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses — At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on…; Change in HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Measurement of HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses — At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on s…; Change in HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Measurement of HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses — At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on si…; Change in HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses — At study weeks 0, 12 and 32 (week 20 on Sirolimus); Measurement of HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses — At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on s…; Change in HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses — At study weeks 0, 12 and 32 (week 20 on Sirolimus)
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.